The only published means of enhancing their immune capacities is to licence WJ‐MSCs with pro‐inflammatory cytokines ,77 for instance IFN‐γ, which improves their function in preventing GVHD in mouse models.49, 78 In the haematopoietic support setting as well, the cell preparation protocol appears to be of great importance to full WJ‐MSC potency. This evidence concerns the gene IFNG and graft versus host disease.